Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK-004
- Development stage
- Preclinical
- Lead developer
- Alkira Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
ALK-004 is a preclinical-stage monoclonal antibody being developed by Alkira Bio for the treatment of obesity and metabolic diseases. Discovered using the company's proprietary LASEREDD® technology platform, the drug is designed to target G protein-coupled receptors (GPCRs), a class of complex membrane proteins that have historically been challenging to target with therapeutic antibodies. While the specific GPCR target and detailed mechanism of action remain undisclosed, the program represents a novel biologic approach to modulating metabolic signaling pathways. The asset originated from research at the Florey Institute of Neuroscience and Mental Health in Melbourne, Australia.
Beyond the preview
Go deeper on ALK-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALK-004.